Xynomic Pharmaceuticals Holdings Inc represents a strong commitment to innovation and excellence in the pharmaceutical industry. The company's corporate philosophy focuses on developing and commercializing breakthrough oncology treatments to improve patients' lives. With a vision to become a global leader in precision medicine, Xynomic Pharmaceuticals prioritizes research and collaboration to unlock the full potential of targeted therapies. The company's core values include integrity, patient-centricity, and scientific rigor. By combining cutting-edge science with a dedication to clinical advancement, Xynomic Pharmaceuticals strives to make a meaningful impact in the field of oncology and bring hope to patients worldwide.

Xynomic Pharmaceuticals Holdings Inc is primarily present in the United States and China.

Xynomic Pharmaceuticals Holdings Inc has achieved significant milestones in its operations. The company successfully completed the Phase 1/2 clinical trials for its lead product candidate, abexinostat, a histone deacetylase inhibitor (HDACi). It has also obtained Fast Track designation from the U.S. FDA for abexinostat in combination with rituximab for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Xynomic has received Orphan Drug Designation from the FDA for its other clinical-stage product, XP-102 (bucillamine), for the treatment of patients with non-alcoholic steatohepatitis. The company's achievements highlight its dedication to advancing innovative therapies for better patient outcomes.

Xynomic Pharmaceuticals Holdings Inc has a rich history and background in the pharmaceutical industry. Established in [insert year], the company has dedicated itself to the development of innovative therapies for various diseases. Xynomic Pharmaceuticals focuses on targeting unmet medical needs, prioritizing patient well-being and improved outcomes. With a strong emphasis on research and development, the company has actively pursued collaborations and partnerships to advance its pipeline of potential drugs. As a leader in the industry, Xynomic Pharmaceuticals continues to strive towards delivering breakthrough treatments that positively impact patients' lives.

The main competitors of Xynomic Pharmaceuticals Holdings Inc in the market include established pharmaceutical companies such as Pfizer, Novartis, Roche, and Johnson & Johnson. These multinational companies have a strong presence in the pharmaceutical industry and offer a wide range of therapeutic products and services. Xynomic Pharmaceuticals Holdings Inc competes with these companies by focusing on its innovative drug development pipeline and unique market positioning.

Xynomic Pharmaceuticals Holdings Inc is primarily active in the biopharmaceutical industry.

The business model of Xynomic Pharmaceuticals Holdings Inc is focused on developing innovative cancer treatments. The company aims to identify and license promising drug candidates, and then advance them through clinical trials and regulatory approval processes. Xynomic Pharmaceuticals uses a strategic approach that combines in-house development with collaborations and partnerships to maximize resources and expertise. By targeting unmet medical needs and leveraging its expertise in oncology, Xynomic Pharmaceuticals aims to bring new and effective treatments to patients worldwide.

P/E santykio šiuo metu Xynomic Pharmaceuticals Holdings apskaičiuoti negalima.

KUV šiuo metu negali būti apskaičiuotas Xynomic Pharmaceuticals Holdings.

AlleAktien kokybės įvertis Xynomic Pharmaceuticals Holdings yra 4/10.

Pajamos šiuo metu negali būti apskaičiuotos Xynomic Pharmaceuticals Holdings.

Pelnas šiuo metu negali būti apskaičiuotas Xynomic Pharmaceuticals Holdings.

Xynomic Pharmaceuticals Holdings Inc is a rising biotech company focused on developing novel therapies for treating various types of cancer. Its business model includes research and development, clinical trials, manufacturing, and distribution of drugs. The company's research and development department is the core of the organization, where experts work on identifying and developing new compounds to combat cancer cells. Clinical trials are conducted to investigate the efficacy and safety of promising drug candidates in humans. Manufacturing involves producing the drug once clinical trials are successfully completed, often in collaboration with external partners. Xynomic Pharmaceuticals currently does not have any drugs on the market but plans to seek FDA approval in the near future. The company has several promising drug candidates, including Abexinostat, XP-105, and XP-102, which have shown positive results in clinical trials. Overall, Xynomic Pharmaceuticals is an emerging biotech company dedicated to developing innovative cancer medications.

Xynomic Pharmaceuticals Holdings moka dividendą 0 USD, kuris yra paskirstytas per išmokas per metus.

Dividenda šiuo metu negali būti apskaičiuota Xynomic Pharmaceuticals Holdings arba įmonė dividendų nemoka.

Xynomic Pharmaceuticals Holdings ISIN yra US98421X1028.

Xynomic Pharmaceuticals Holdings akcijų simbolis yra XYNO.

Per paskutinius 12 mėnesių Xynomic Pharmaceuticals Holdings išmokėjo dividendą, kurios dydis siekė . Tai atitinka maždaug dividendų grąžą. Artimiausiems 12 mėnesiams Xynomic Pharmaceuticals Holdings tikėtina išmokės dividendus, kurie sudarys 0 USD.

Xynomic Pharmaceuticals Holdings šiuo metu yra dydžio dividendų grąža.

Xynomic Pharmaceuticals Holdings moka dividendus kas ketvirtį. Jie išmokami mėnesiais.

Xynomic Pharmaceuticals Holdings per paskutiniuosius 0 metus kiekvienais metais mokėjo dividendus.

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0 USD. Tai atitinka 0 % dividendų grąžos procentą.

Xynomic Pharmaceuticals Holdings priskiriamas sektoriui "Sveikata".

Norėdamas gauti paskutinį Xynomic Pharmaceuticals Holdings dividendą nuo 2025-02-07, kurio dydis yra 0 USD, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2025-02-07.

Paskutinės dividendų išmokėjimas įvyko 2025-02-07.

2024 metais Xynomic Pharmaceuticals Holdings išmokėjo 0 USD dividendų.

Xynomic Pharmaceuticals Holdings dividendai yra mokami USD.